How Is The Global Hereditary Cancer Testing Market Shaping Up?
The hereditary cancer testing market size has seen significant growth in recent years, increasing from a valuation of $4.32 billion in 2024 to an estimated $4.78 billion in 2025. This impressive growth, marking a compound annual growth rate (CAGR) of 10.8%, can be predominantly attributed to factors such as rising incidence of hereditary cancers, structured genetic counseling programs, government initiatives for cancer prevention, improved insurance coverage, and an increasing understanding of gene-environment interactions. In addition, a significant role has been played by patient advocacy and support groups in driving the market’s growth.
Looking to the future, further rapid growth is anticipated for the hereditary cancer testing market, with forecasts predicting a market value of $7.37 billion in 2029; a CAGR of 11.4%. Key drivers of this growth in the forecast period are expected to be the expansion of targeted therapies, advancements in precision medicine, the rise in direct-to-consumer testing, global health initiatives, and advancements in bioinformatics. The evolving landscape of the market is also likely to be influenced by major trends such as advancements in genetic sequencing technologies, the emergence of telemedicine and remote genetic counseling, precision medicine, personalized treatment, cancer risk assessment models, and ethical and legal considerations.
Get Your Free Sample of The Global Hereditary Cancer Testing Market Report here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8121&type=smp
What Are The Key Drivers Of The Hereditary Cancer Testing Market?
A significant driver of the hereditary cancer testing market is the increasing prevalence of hereditary cancer. Mutations in specific genes passed from parents to children cause hereditary cancer syndromes. Hereditary cancer testing can identify these specific, heritable, disease-related gene mutations, enabling a comprehensive cancer risk assessment for patients. An exemplification of this can be seen with the findings published in a June 2022 article on BioMed Central about hereditary cancer in clinical practice. The findings highlighted that approximately 10% of pancreatic cancer cases have a genetic background, thereby emphasizing the crucial role that the increasing prevalence of hereditary cancer, specifically, is playing in driving the growth of the hereditary cancer testing market.
What Are The Key Segments In The Hereditary Cancer Testing Market?
The hereditary cancer testing market can be segmented into:
1) Test Type: Multi Panel Test, Single-Site Genetic Test
2) Indication: Breast Cancer, Ovarian Cancer, Colorectal Cancer, Other Indications
3) End user: Hospital, Clinics, Diagnostic Centers
You can access the full report here for swift delivery:
https://www.thebusinessresearchcompany.com/report/hereditary-cancer-testing-global-market-report
Who Are The Major Players In The Hereditary Cancer Testing Market?
Key players in the hereditary cancer testing market are Centogene NV, Ambry Genetics Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Quest Diagnostics, PreventionGenetics, Fulgent Genetics Inc., Invitae Corporation, Medical Diagnostic Laboratories LLC, Natera Inc., Color Health Inc., CooperSurgical Inc., OPKO Health Inc., Illumina Inc., Laboratory Corporation of America Holdings, Pathway Genomics Corporation, Strand Life Sciences Private Limited, Progenity Inc., Myogenes Ltd., Associated Regional and University Pathologists Inc., 4baseCare, Biocartis Group NV, F. Hoffmann-La Roche AG, Medgenome Pvt. Ltd., Abbott Laboratories, Agilent Technologies Inc., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Oxford Nanopore Technologies PLC, PerkinElmer Inc.
What Trends Are Emerging In The Hereditary Cancer Testing Market?
A key trend gaining popularity in the hereditary cancer testing market is technological innovation. Key players in the market are focusing on technological innovations to sustain their market positions. For instance, in March 2022, Myriad Genetics, a US-based genetic testing and precision medicine company, launched genetic testing with a Polygenic Breast Cancer Risk Assessment Score for all ancestries. This MyRisk Hereditary Cancer test with RiskScore offers a personalized breast cancer risk assessment to all women who have never been diagnosed with breast cancer, regardless of ancestry.
What Is The Regional Analysis Of The Hereditary Cancer Testing Market?
In 2024, North America was the largest region in the hereditary cancer testing market. The report covers other regions including Asia-Pacific, Western Europe, Eastern Europe, South America, Middle East, and Africa.
What Does The Hereditary Cancer Testing Market Report 2025 Offer?
The hereditary cancer testing refers to testing methods for hereditary cancers that can identify specific hereditary cancer diseases and disease-related gene mutations. This testing may decrease the risk of developing particular cancer mutants, allowing a more comprehensive cancer risk for patients. The primary aim of this cancer testing is to detect hereditary cancer early and maximize patient health outcomes. This testing procedure assists in identifying cancers for which one has a genetic risk, enabling preventative treatment.
The Hereditary Cancer Testing Market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8121
About The Business Research Company
Learn More About the Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
